Adrenergic beta-antagonists (beta-blockers) in COPD patients

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F14%3A10283827" target="_blank" >RIV/00179906:_____/14:10283827 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11150/14:10283827
Result on the web
<a href="http://www.minervamedica.it/en/journals/minerva-pneumologica/article.php?cod=R16Y2014N04A0167" target="_blank" >http://www.minervamedica.it/en/journals/minerva-pneumologica/article.php?cod=R16Y2014N04A0167</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Adrenergic beta-antagonists (beta-blockers) in COPD patients
Original language description
Chronic obstructive pulmonary disease (COPD) is a serious condition, which leads to decreased quality of life, increased morbidity and is a frequent cause of mortality. Frequently, patients diagnosed with COPD suffer from other comorbidities, the most prevalent being cardiovascular and neurological. Adrenergic beta-antagonists or beta-blockers (BBs) represent a group of drugs that are being used mainly in patients with various cardio-vascular diseases. As cardiovascular commorbidities are common in patients treated for COPD, the main effect of BBs in respiratory system related to vasoconstriction constitutes a concern for the safety of their use in COPD patients. This article reviews current published data on effects of BBs in COPD patients with concomitant heart condition and observed benefits and potential adverse effects of BBs in these patients.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FC - Pneumology
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)